

SHORT REPORT

Open Access



Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Songjie Wu^{1†}, Yubin Zhang^{2†}, Fangzhao Ming^{2†}, Shi Zou³, Mengmeng Wu³, Wei Guo^{4,5}, Weiming Tang^{6,7*} and Ke Liang^{1,3,8,9,10*} 

Abstract

This study aims to evaluate the safety of inactivated COVID-19 vaccine among adult people living with HIV (PLWH). In total, 259 PLWH who received at least one dose of inactivated COVID-19 vaccine were enrolled, and post-vaccination adverse events (AEs) were evaluated seven days following each vaccination dose. The overall AE frequency was 22.8% after dose one, which was higher than after dose two (10.2%) ($P < 0.001$). No severe side event or vaccine safety concern was observed. Our finding was essential in reducing vaccine hesitancy among PLWH.

Keywords: People living with HIV(PLWH), COVID-19, Inactivated vaccine, Adverse event

People living with HIV (PLWH) tend to have high COVID-19 related morbidity and mortality [1]. UNAIDS suggested that PLWH should be given priority in COVID-19 vaccinations regardless of CD4 + T lymphocyte count (CD4 count) and HIV viral load (HIV-VL) levels [2]. The Chinese guideline also suggested that PLWH be given the inactivated vaccine or the recombinant subunit vaccine [3]. However, the safety of COVID-19 vaccines among PLWH in China is unknown. This study aims to estimate the adverse events (AEs) rate after COVID-19 vaccination among PLWH.

Between April and July 2021, PLWH from the Wuchang district of Wuhan, China, aged between 18 and 59 years, were enrolled in this study. All participants received inactivated COVID-19 vaccine (Sinopharm, Wuhan Institute

of Biological Products Co. Ltd.) on day 0 and day 28 by intramuscular injection. Post-vaccination adverse events were evaluated seven days after each dose of vaccination. These adverse events include injection site pain, swelling, redness, fever, headache, fatigue, drowsiness, and cough.

In total, 91.1% of the PLWH (236/259) have taken both doses, while the remaining 8.9% have only taken the first dose of inactivated vaccine. Of all participants, 99.2% were on antiretroviral therapy (ART), 80.3% were virally suppressed (208/259), and 81.1% had CD4 count > 350 cells/ μ l (210/259) at enrollment (Table 1).

The overall AE rate was 22.8% after dose one (D1) of the vaccination, which was higher than that after dose two (10.2%) ($P < 0.001$). Local injection-site reactions were reported in 17.0% of the participants after D1 and 7.6% after D2. The most common systemic reactions included fatigue (3.5% after D1, and 0.8% after D2, drowsiness (2.3% after D1, and 1.7% after D2), fever (1.9% after D1, and 0.0% after D2) (Fig. 1).

The majority of AEs were non-severe. The most common severe symptom after D1 included fatigue (3.1%), drowsiness (2.3%), and dizziness (1.9%). The most common severe symptom after D2 was drowsiness (1.7%). No other severe adverse events were observed. Compared with participants with other ART regimens (7.6%),

*Correspondence: Weiming_tang@med.unc.edu; keliang@whu.edu.cn

[†]Songjie Wu Yubin Zhang and Fangzhao Ming contributed equally to this work

⁷The University of North Carolina at Chapel Hill Project-China, Guangzhou, China

¹⁰Department of Nosocomial Infection Management, Department of Infectious Diseases Center of Preventing Mother-To-Child Transmission for Infectious Diseases, Wuhan Research Center for Infectious Diseases and Cancer Chinese Academy of Medical Sciences, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.


Table 1 Baseline data for all participants

Characteristic	Patients with HIV/AIDS (n = 259)	Dose 1 (N = 259)				Dose 2 (N = 236)			
		With adverse events	Without adverse events	χ^2	P	With adverse events	Without adverse events	χ^2	P
Age group									
≤ 35	116	30	86			11	89		
> 35	143	29	114	1.14	0.29	13	123	0.13	0.72
Gender									
Male	240	55	185			21	197		
Female	19	4	15	0.04	0.85	3	15	0.90	0.34
Marital status									
Singe	169	42	127			17	136		
Married	36	6	30			3	31		
Other	54	11	43	1.36	0.51	4	45	0.43	0.81
Occupation									
Unemployment	37	7	30			2	33		
Employment	222	52	170	0.37	0.55	22	179	0.89	0.35
Education level									
High school or lower	76	17	59			6	62		
Higher than high school	183	42	141	0.01	0.92	18	150	0.19	0.66
Comorbidities									
Yes	38	6	32			5	30		
No	221	53	168	1.24	0.27	19	182	0.76	0.38
NNRTIs (NVP/EFV)									
Yes	216	47	169			17	180		
No	43	12	31	0.77	0.38	7	32	–	0.09
INSTIs (EVG/DTG)									
Yes	26	5	21			1	22		
No	233	54	179	0.21	0.65	23	190	–	0.48
PIs (LPV/r)									
Yes	14	5	9			5	8		
No	245	54	191	0.74	0.39	19	204	9.00	0.003
CD4									
≤ 350	49	8	41			5	38		
> 350	210	51	159	1.43	0.23	19	174	0.12	0.73
HIV viral load									
Undetectable	208	49	159			19	172		
Detectable	51	10	41	0.36	0.55	5	40	–	0.79

NNRTIs nonnucleoside reverse transcriptase inhibitors; INSTIs integrase inhibitors; PIs protein inhibitors; NVP nevirapine; EFV efavirenz; EVG elvitegravir; DTG dolutegravir; LPV/r lopinavir/ritonavir; – no statistics are computed because Fisher exact method was used

participants receiving protein inhibitor (PI) based antiretroviral regimen (all PI is lopinavir/ritonavir) reported more AEs (38.5%) after D2 ($P < 0.05$). No significant differences in any AE rates were observed in other subgroups of PLWH ($P > 0.05$). After adjusted for age, sex,

comorbidities, CD4 count, and HIV viral load with multi-variable logistic regression model, receiving LPV/r based regimen were still associated with increased AE risk in D2 (OR = 11.92, 95% CI 2.63–54.00; $P = 0.001$) (Table 2). We also found no difference in AE rates after each dose



between participants with CD4 >350/ μ L and $\leq$ 350/ μ L ($P > 0.05$).

Concerns around AEs significantly impact ongoing vaccine hesitancy among PLWH. A previous national survey found that about 37.1% of PLWH are concerned that COVID-19 vaccination may have severe side effects [4]. Our study extended the existing literature by reporting AEs after COVID-19 vaccination among PLWH [5–7]. In our study, the AE rates were 22.8% after dose one (D1) of the inactivated COVID-19 vaccination and 10.2% after dose two, which was not higher than the AE rates of the original inactivated COVID-19 vaccine trials in general population [8, 9]. The AE rates of inactivated COVID-19 vaccine in our study was lower than that of mRNA COVID-19 vaccine [5, 6, 10] and adenovirus vector COVID-19 vaccine [7]. We conclude the adverse events after the two-dose of inactivated COVID-19 vaccination among PLWH are minimal and mild. In addition, we also found that participants who were receiving LPV/r based regimen were more likely to experience AE after D2.

Our results have direct and immediate clinical implications. The data in this analysis are reassuring, finding no severe adverse event or vaccine safety concern among PLWH. There is an urgent need to disseminate this information to the vulnerable group of PLWH to minimize vaccine hesitancy and eliminate its refusal.

Table 2 Risk factors associated with AEs of inactivated COVID-19 vaccine in HIV-infected adults after dose 1 and dose 2: multivariable logistic regression analysis

Item	Dose 1		Dose 2	
	Adjusted OR ^a (95% CI)	P	Adjusted OR ^a (95% CI)	P
Age				
≤ 35	Ref.		Ref.	
> 35	0.68 (0.37, 1.26)	0.22	0.58 (0.22, 1.49)	0.26
Gender				
Male	Ref.		Ref.	
Female	1.03 (0.32, 3.34)	0.96	2.54 (0.62, 10.41)	0.20
Comorbidities				
No	Ref.		Ref.	
Yes	0.66 (0.26, 1.70)	0.39	1.85 (0.60, 5.71)	0.28
PIs (LPV/r)				
No	Ref.		Ref.	
Yes	2.97 (0.86, 10.30)	0.09	11.92 (2.63, 54.00)	0.001
CD4				
≤ 350	Ref.		Ref.	
> 350	1.71 (0.72, 4.09)	0.23	1.26 (0.39, 4.13)	0.70
HIV viral load				
Undetectable	Ref.		Ref.	
Detectable	0.74 (0.32, 1.69)	0.47	0.58 (0.15, 2.24)	0.43

^a Each association was mutually adjusted for the other characteristics in the table

Acknowledgements

Not applicable.

Authors' contributions

KL and WT participated in the inception of the idea of this manuscript with lead roles in conducting the study; SW involved in the data analysis and drafting of the manuscript; YZ and FM involved in data collection and interpretation; SZ, MW and WG was participated in discussion section. All authors read and approved the final manuscript.

Funding

This work was supported by the National Key Research and Development Program of China (2017YFE0103800), the National Nature Science Foundation of China (81903371), NIMH (R34MH119963), the National Science and Technology Major Project (2018ZX10101-001-001-003), and Special Found on Prevention and Control of New Coronary Pneumonia in Guangdong Universities (2020KZDZX1047), Medical Science and Technology Innovation Platform Support Project of Zhongnan Hospital, Wuhan University (PTXM2020008), Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University (cxpy2017043). Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018004).

Availability of data and materials

All data generated or analyzed during this study are included in this article. The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations**Ethics approval and consent to participate**

This study was approved by the Research and Ethics Committee of Zhongnan Hospital, Wuhan University, People's Republic of China (2020079K-1), and informed consent was obtained.

Consent for the publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Nosocomial Infection Management, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. ²Wuchang District Center for Disease Control and Prevention, Wuhan, Hubei, China. ³Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. ⁴Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China. ⁵Department of Pathology, School of Basic Medical Sciences, Wuhan University, Wuhan, China. ⁶Guangdong No. 2 Provincial People's Hospital, University of North Carolina at Chapel Hill Project-China, Guangzhou 510095, China. ⁷The University of North Carolina at Chapel Hill Project-China, Guangzhou, China. ⁸Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, China. ⁹Center of Preventing Mother-To-Child Transmission for Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China. ¹⁰Department of Nosocomial Infection Management, Department of Infectious Diseases Center of Preventing Mother-To-Child Transmission for Infectious Diseases, Wuhan Research Center for Infectious Diseases and Cancer Chinese Academy of Medical Sciences, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Received: 19 August 2021 Accepted: 17 November 2021
Published online: 04 December 2021

References

- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. *JAMA*. 2020;323(13):1239–42.
- UNAIDS. COVID-19 vaccines and HIV. <https://www.unaids.org/en/resources/documents/2021/covid19-vaccines-and-hiv>. Accessed 14 Feb 2021.
- Central People's Government of the People's Republic of China. Technical guidelines for the COVID-19 vaccination (First Edition). 2021. http://www.gov.cn/xinwen/2021-03/29/content_5596577.htm. Accessed 26 May 2021.
- Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 vaccine hesitancy among French people living with HIV. *Vaccines*. 2021;9(4):302.
- Ruddy JA, Boyarsky BJ, Werbel WA, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, Durand CM. Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV. *AIDS*. 2021. <https://doi.org/10.1097/QAD.0000000000003017>.
- Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, Durand CM, Werbel WA. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. *AIDS*. 2021. <https://doi.org/10.1097/QAD.0000000000003017>.
- Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Aley PK, Bhikha S, Hermanus T, Horne E, Jose A, Kgagudi P, Lambie T, Masanya M, Masilela M, Mkhize N, Moultrie A, Mukendi CK, Moyo-Gwete T, Nana AJ, Nzimande A, Patel F, Rhead S, Taoushanis C, Thombrayil A, van Eck S, Voysey M, Villafana TL, Vekemans J, Gilbert SC, Pollard AJ, Moore PL, Kwatra G. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. *Lancet HIV*. 2021;8(9):e568–80.
- Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. *JAMA*. 2020;324(10):951–60.
- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis*. 2021;21(1):39–51.
- Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, Huppert A, Mor O, Goldstein M, Levin EG, Hod T, Cohen C, Lustig Y, Rahav G. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. *Clin Microbiol Infect*. 2021;S1198–743X(21):00423–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

